SCHEMBL4276574

SCHEMBL4276574

CCCCCCCCCCOc1ccc(C(=O)Oc2ccc(-c3ccc(O[C@@H](C)CCCC[Si](C)(C)O[Si](C)(C)C)c([N+](=O)[O-])c3)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G4B P0C869 1/20 0.45
LMNA P02545 5/20 0.42
NPC1 O15118 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
NFKB1 P19838 3/20 0.42
NFKB2 Q00653 3/20 0.42
RELA Q04206 3/20 0.42
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
RARB P10826 3/20 0.38
MAPT P10636 3/20 0.38
POLB P06746 1/20 0.38
PRSS1 P07477 1/20 0.37
ACR P10323 1/20 0.37
KMT2A Q03164 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3272113 1.00 PLA2G4B (0.45) PLA2G4BLMNANPC1SMN1; SMN2NFKB1
SCHEMBL4271615 0.98 PLA2G4B (0.46) PLA2G4BLMNANPC1SMN1; SMN2NFKB1
SCHEMBL3277481 0.92 MAPT (0.40) PLA2G4BSMN1; SMN2RARBMAPTKMT2A
SCHEMBL4270500 0.91 PLA2G4B (0.52) PLA2G4BLMNANPC1SMN1; SMN2NFKB1
SCHEMBL29382893 0.91 PLA2G4B (0.52) PLA2G4BLMNANPC1SMN1; SMN2NFKB1
SCHEMBL8924412 0.91 PLA2G4B (0.52) PLA2G4BLMNANPC1SMN1; SMN2NFKB1
SCHEMBL12636637 0.91 PLA2G4B (0.40) PLA2G4BLMNANPC1SMN1; SMN2NFKB1
SCHEMBL1877602 0.88 PLA2G4B (0.46) PLA2G4BLMNANPC1SMN1; SMN2NFKB1
SCHEMBL3274736 0.88 NPC1 (0.44) PLA2G4BLMNANPC1SMN1; SMN2NFKB1
SCHEMBL8926782 0.87 PLA2G4B (0.53) PLA2G4BLMNANPC1SMN1; SMN2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615165-B2 Liquid crystal molecule, liquid crystal display and liquid crystal optical spatial modulation device SONY CORPORATION (JP) 2009-11-10 US disclosed
EP-1935961-A1 Liquid crystal molecule, liquid crystal display device and liquid crystal optical spatial modulation device Sony Corporation (JP) 2008-06-25 EP disclosed
US-20080143950-A1 LIQUID CRYSTAL MOLECULE, LIQUID CRYSTAL DISPLAY DEVICE AND LIQUID CRYSTAL OPTICAL SPATIAL MODULATION DEVICE SONY CORPORATION (JP) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080143950-A1 LIQUID CRYSTAL MOLECULE, LIQUID CRYSTAL DISPLAY DEVICE AND LIQUID CRYSTAL OPTICAL SPATIAL MODULATION DEVICE DVL1, CXCR1, LASP1 PLA2G4B 2566/4885LMNA 4139/4885NPC1 3291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.